Trends in Antibacterial Use in US Academic Health Centers
作者： Amy L. Pakyz , Conan MacDougall , Michael Oinonen , Ronald E. Polk
DOI: 10.1001/ARCHINTE.168.20.2254
关键词:
摘要: Background Antibacterial drug use is a major risk factor for bacterial resistance, but little known about antibacterial in US hospitals. The objectives of this study were to characterize trends sample hospitals and identify predictors use. Methods We measured systemic from validated claims data at 22 university teaching January 1, 2002, through December 31, 2006, we examined potential including hospital patient demographics stewardship policies. Results A total 775 731 adult patients discharged 35 during 492 721 (63.5%) received an drug. mean (SD) increased 798 (113) days therapy per 1000 2002 855 (153) 2006 ( P Conclusions Total adults significantly academic health centers, driven by increases the broad-spectrum agents vancomycin. These developments have important implications acquired resistance among nosocomial pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA).
sci-hub.se 参考文章(36)
Herbert A. Kirst, Diane G. Thompson, Thalia I. Nicas, Historical Yearly Usage of Vancomycin Antimicrobial Agents and Chemotherapy. ,vol. 42, pp. 1303- 1304 ,(1998) , 10.1128/AAC.42.5.1303
Jeffrey A. Linder, Elbert S. Huang, Michael A. Steinman, Ralph Gonzales, Randall S. Stafford, Fluoroquinolone prescribing in the United States: 1995 to 2002 The American Journal of Medicine. ,vol. 118, pp. 259- 268 ,(2005) , 10.1016/J.AMJMED.2004.09.015
Lindsay M Arnold, Michael A Crouch, Norman V Carroll, Michael J Oinonen, Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy. ,vol. 26, pp. 1078- 1085 ,(2006) , 10.1592/PHCO.26.8.1078
Eileen R. Sherman, Kateri H. Heydon, Keith H. St. John, Eva Teszner, Susan L. Rettig, Sharon K. Alexander, Theoklis Z. Zaoutis, Susan E. Coffin, Administrative Data Fail to Accurately Identify Cases of Healthcare-Associated Infection Infection Control and Hospital Epidemiology. ,vol. 27, pp. 332- 337 ,(2006) , 10.1086/502684
Leanne B. Gasink, Neil O. Fishman, Mark G. Weiner, Irving Nachamkin, Warren B. Bilker, Ebbing Lautenbach, Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. The American Journal of Medicine. ,vol. 119, pp. 526- ,(2006) , 10.1016/J.AMJMED.2005.11.029
Jérôme Robert, Roland Bismuth, Vincent Jarlier, Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983–2002 Journal of Antimicrobial Chemotherapy. ,vol. 57, pp. 506- 510 ,(2006) , 10.1093/JAC/DKI486
J. B. Patel, L. A. Jevitt, J. Hageman, L. C. McDonald, F. C. Tenover, An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clinical Infectious Diseases. ,vol. 42, pp. 1652- 1653 ,(2006) , 10.1086/504084
Javier Ena, The Epidemiology of Intravenous Vancomycin Usage in a University Hospital JAMA. ,vol. 269, pp. 598- 602 ,(1993) , 10.1001/JAMA.1993.03500050076029
Sebastian Schneeweiss, Jerry Avorn, A review of uses of health care utilization databases for epidemiologic research on therapeutics Journal of Clinical Epidemiology. ,vol. 58, pp. 323- 337 ,(2005) , 10.1016/J.JCLINEPI.2004.10.012
G. Wang, J. F. Hindler, K. W. Ward, D. A. Bruckner, Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. Journal of Clinical Microbiology. ,vol. 44, pp. 3883- 3886 ,(2006) , 10.1128/JCM.01388-06